摘要:
The invention comprises a medicinal aerosol composition comprising a propellant, an excipient comprising an acid or amine end-group and at least one and no more than two amide and/or ester functional groups, and a drug. The invention also comprises particulate medicinal compositions comprising particles with a mean mass aerodynamic diameter of less than about 10 microns that incorporate an excipient containing an acid or amine end-group and at least one and no more than two amide and/or ester functional groups.
摘要:
The invention relates to stabilized dispersions containing nanoparticles of use for the administration of medicaments. The dispersions comprise excipient nanoparticles, a dispersed phase comprising medicament and a continuous phase comprising propellant.
摘要:
Methods for the manufacture of medicinal compositions are described. A method for the manufacture of a medicinal composition according to the invention comprises: (a) Providing a biocompatible polymer of the general formula —[O—R1—C(O)]n— wherein: “R1” is a linear, branched, or cyclic organic group, “n” is at least three, (b) Acylating the biocompatible polymer to provide an acylated biocompatible polymer and a mixed anhydride; (c) Reacting the mixed anhydride with a nucleophile to provide an acylated biocompatible polymer with a terminal carboxylic acid derivative capable of being chemically converted to an acid in the absence of water, (d) Converting the terminal carboxylic acid derivative to an acylated biocompatible polymer with a terminal carboxylic acid; and (e) Combining the acylated biocompatible polymer with a drug to provide the medicinal composition.
摘要翻译:描述了药物组合物的制造方法。 制备根据本发明的药物组合物的方法包括:(a)提供具有通式的生物相容性聚合物 - [OR 1 -C 2 -C(O)] n SUB >其中:“R 1”是直链,支链或环状有机基团,“n”为至少三个,(b)酰化生物相容性聚合物以提供酰化生物相容性聚合物和混合 酐; (c)用亲核试剂反应混合酸酐以提供酰化的生物相容性聚合物,其具有能够在不存在水的情况下化学转化为酸的末端羧酸衍生物; (d)将末端羧酸衍生物与末端羧酸转化成酰化生物相容性聚合物; 和(e)将酰化的生物相容性聚合物与药物组合以提供药物组合物。
摘要:
Azlactone-functional membranes prepared by solvent phase inversion techniques are disclosed. Adduct membranes prepared by the reaction of azlactone-functional membranes with nucleophilic reagents are also disclosed. Both azlactone-functional copolymers and blends of azlactone-functional homopolymers or copolymers with blending polymers can be used. These azlactone-functional membranes have azlactone functionality throughout all surfaces formed ab initio into any desired shape. Membrane properties can be modified by sacrifice of some azlactone functionality via crosslinking between azlactone moieties or coupling of hydrophilic ligands.
摘要:
Methods of impregnating various polymer substrates with an impregnation additive, by simultaneously contacting the polymer substrate with an impregnation additive, carrier liquid, and supercritical fluid are provided. The impregnation additive is substantially insoluble in the supercritical fluid, and the carrier liquid is preferably substantially insoluble in the supercritical fluid.
摘要:
A pharmaceutical aerosol formulation includes a therapeutically effective amount of particulate medicament of formula (I) or a solvate thereof, a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoro-n-propane or mixtures thereof, and a biocompatible polymer comprising one or more compounds of formula (II)
摘要:
In one aspect, the invention provides a stable dispersion comprising a continuous phase comprising a continuous liquid phase and a plurality of organic nanoparticles; and a dispersed phase comprising particles dispersed in the continuous phase.
摘要:
In one aspect, the invention provides a stable dispersion comprising a continuous phase comprising a continuous liquid phase and a plurality of organic nanoparticles; and a dispersed phase comprising particles dispersed in the continuous phase.
摘要:
Methods, compounds, and medicinal formulations utilizing biocompatible polymers for delivery of a drug, particularly for solubilizing, stabilizing and/or providing sustained release of drug from topical, implantable, and inhalation systems. Many of the methods, compounds, and medicinal formulations are particularly suitable for oral and/or nasal inhalation and use polymers of the formula --[X--R.sup.1 --C(O)]-- wherein each R.sup.1 is an independently selected organic group that links the --X-- group to the carbonyl group, and each X is independently oxygen, sulfur, or catenary nitrogen.